Skip to main content

Metronidazole exposure-response and safety in infants.

Publication ,  Journal Article
Randell, RL; Balevic, SJ; Greenberg, RG; Cohen-Wolkowiez, M; Smith, MJ; Benjamin, DK; Bendel, C; Bliss, JM; Chaaban, H; Chhabra, R; Downey, LC ...
Published in: Antimicrob Agents Chemother
November 5, 2025

The nitroimidazole antibiotic, metronidazole, is frequently prescribed to infants with serious intra-abdominal infections, and multiple dosing recommendations exist. We sought to evaluate the extent to which metronidazole doses and associated exposures achieved desired efficacy and safety in infants enrolled in the Antibiotic Safety in Infants with Complicated Intra-abdominal Infections (SCAMP) trial (NCT01994993). SCAMP participants received intravenous metronidazole as part of multimodal antimicrobial therapy. Participants received a 15 mg/kg loading dose and a 7.5 mg/kg maintenance dose at 24 h. A subsequent 7.5 mg/kg maintenance dose was administered every 12 h for participants of postmenstrual age (PMA) 23 to <34 weeks; 8 h for PMA 34-40 weeks; and 6 h for PMA >40 weeks. We evaluated associations between simulated metronidazole exposures and pre-specified surrogate pharmacodynamic targets and clinical outcomes of efficacy and safety. Nearly 100% of pharmacodynamic targets were met. Infants with therapeutic success (a composite efficacy outcome, defined as the absence of death, negative bacterial blood cultures, and presumptive clinical cure at 30 days) had higher Cmin,ss, Cmax,ss, AUC00-24,ss, and AUCcum compared with infants without therapeutic success. However, the relationships between these exposure measures and therapeutic success were not significant in logistic regression analysis adjusting for gestational age. Despite generally high simulated exposures, no relationships were observed between exposures and prespecified safety events (necrotizing enterocolitis, intestinal strictures, intestinal perforation, positive blood culture, seizures, death, and intraventricular hemorrhage). Findings support metronidazole dosing as administered in term and preterm infants in the SCAMP trial.

Duke Scholars

Published In

Antimicrob Agents Chemother

DOI

EISSN

1098-6596

Publication Date

November 5, 2025

Volume

69

Issue

11

Start / End Page

e0037725

Location

United States

Related Subject Headings

  • Microbiology
  • Metronidazole
  • Male
  • Intraabdominal Infections
  • Infant, Newborn
  • Infant
  • Humans
  • Female
  • Enterocolitis, Necrotizing
  • Anti-Bacterial Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Randell, R. L., Balevic, S. J., Greenberg, R. G., Cohen-Wolkowiez, M., Smith, M. J., Benjamin, D. K., … Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. (2025). Metronidazole exposure-response and safety in infants. Antimicrob Agents Chemother, 69(11), e0037725. https://doi.org/10.1128/aac.00377-25
Randell, Rachel L., Stephen J. Balevic, Rachel G. Greenberg, Michael Cohen-Wolkowiez, Michael J. Smith, Daniel K. Benjamin, Catherine Bendel, et al. “Metronidazole exposure-response and safety in infants.Antimicrob Agents Chemother 69, no. 11 (November 5, 2025): e0037725. https://doi.org/10.1128/aac.00377-25.
Randell RL, Balevic SJ, Greenberg RG, Cohen-Wolkowiez M, Smith MJ, Benjamin DK, et al. Metronidazole exposure-response and safety in infants. Antimicrob Agents Chemother. 2025 Nov 5;69(11):e0037725.
Randell, Rachel L., et al. “Metronidazole exposure-response and safety in infants.Antimicrob Agents Chemother, vol. 69, no. 11, Nov. 2025, p. e0037725. Pubmed, doi:10.1128/aac.00377-25.
Randell RL, Balevic SJ, Greenberg RG, Cohen-Wolkowiez M, Smith MJ, Benjamin DK, Bendel C, Bliss JM, Chaaban H, Chhabra R, Dammann CEL, Downey LC, Hornik CD, Hussain N, Laughon MM, Lavery A, Moya F, Saxonhouse M, Sokol GM, Trembath A, Weitkamp J-H, Hornik CP, Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Metronidazole exposure-response and safety in infants. Antimicrob Agents Chemother. 2025 Nov 5;69(11):e0037725.

Published In

Antimicrob Agents Chemother

DOI

EISSN

1098-6596

Publication Date

November 5, 2025

Volume

69

Issue

11

Start / End Page

e0037725

Location

United States

Related Subject Headings

  • Microbiology
  • Metronidazole
  • Male
  • Intraabdominal Infections
  • Infant, Newborn
  • Infant
  • Humans
  • Female
  • Enterocolitis, Necrotizing
  • Anti-Bacterial Agents